Novo Nordisk Investigational Site

Detroit, Michigan 48236

0 studies enrolling now · 25 studies all time

What they study most

Acquired Bleeding Disorder, Chronic Kidney Disease, Congenital Bleeding Disorder, Congenital FXIII Deficiency, Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, End-Stage Renal Disease, Haemophilia A, Haemophilia A With Inhibitors, Haemophilia B, Haemophilia B With Inhibitors

Studies at this site

• A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A — Completed
• A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6) — Completed
• Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis. — Completed
• Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes — Completed
• Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A — Completed
• Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A — Completed
• Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes — Completed
• A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia — Completed
• A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events — Completed
• Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study — Completed
• Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes — Completed
• Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 — Completed
• Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A — Completed
• Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens — Completed
• The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis — Stopped early
• Comparison of Two Insulin Degludec Formulations in Subjects With Type 2 Diabetes Mellitus — Completed
• Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency — Completed
• Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency — Completed
• Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes — Completed
• Recombinant Factor VIIa in Acute Intracerebral Haemorrhage — Completed
• Trial of NovoSeven® in Haemophilia - Joint Bleeds — Completed
• Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia — Completed
• Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes — Completed
• Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents — Completed
• Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes — Completed